Increasing Incidence of Nalidixic Acid-Resistant Non-Typhi Salmonella: FoodNet and NARMS 1996-2002

Jennifer M. Nelson<sup>1,2</sup>, D. Vugia<sup>3</sup>, A. Daniels<sup>4</sup>, S. Hurd<sup>5</sup>, M. Park<sup>6</sup>, D. Blythe<sup>7</sup>, S. Wedel<sup>8</sup>, B. Anderson<sup>9</sup>, A. Ingram<sup>10</sup>, K. Joyce<sup>1</sup>, F.J. Angulo<sup>1</sup>, and the EIP FoodNet and NARMS Working Groups

<sup>1</sup>CDC, Atlanta, GA, <sup>2</sup>Atlanta Education and Research Foundation, Atlanta, GA, <sup>3</sup>CA Dept of Health Svcs, Berkeley, CA, <sup>4</sup>CO Dept Public Health and Environment, Denver, CO, <sup>5</sup>CT EIP, New Haven, CT, <sup>6</sup>GA Dept Public Health, Atlanta, GA, <sup>7</sup>MD Dept Health and Mental Hygiene, Baltimore, MD, <sup>8</sup>MN Dept of Health, Minneapolis, MN, <sup>9</sup>NYS Dept of Health, Albany, NY, <sup>10</sup>TN Dept of Health, Nashville, TN,

**Introduction:** Salmonella is a major cause of foodborne illness. Antimicrobial treatment is usually not essential but may be lifesaving. Resistance to nalidixic acid, an elementary quinolone, is associated with a decreased susceptibility to ciprofloxacin, a fluoroquinolone. Fluoroquinolones are used in adults with Salmonella infections and in food animal production. Emergence of nalidixic acid-resistant Salmonella signals the potential for emergence of ciprofloxacin resistance.

**Methods:** From 1996-2002, state health departments participating in the National Antimicrobial Resistance Monitoring System (NARMS) forwarded every tenth human non-Typhi *Salmonella* isolate to CDC for susceptibility testing. Nalidixic acid resistance was defined as a MIC  $\geq$  32  $\mu$ g/ml. NARMS data were used to determine the change in the prevalence of nalidixic acid resistance from 1996 to 2002. FoodNet conducted active surveillance at clinical laboratories to ascertain all laboratory-diagnosed *Salmonella* infections. FoodNet data were used to determine the change in incidence of non-Typhi *Salmonella* from 1996 to 2002. FoodNet and NARMS data were merged to estimate the change in incidence of nalidixic acid-resistant non-Typhi *Salmonella* from 1996 to 2002.

**Results:** From 1996-2002, 1.3% (65/4853) of non-Typhi *Salmonella* isolates submitted to NARMS from FoodNet sites were nalidixic acid resistant -- 0.7% (4/588) in 1996 compared with 1.7% (13/760) in 2002. The annual modeled incidence of non-Typhi *Salmonella* infections in FoodNet did not change substantially from 1996 (15.7/100,000) to (14.8/100,000) in 2002. Multiplying the modeled FoodNet non-Typhi *Salmonella* incidence by the NARMS proportion of nalidixic acid-resistant isolates from the FoodNet sites, the estimated incidence of nalidixic acid-resistant non-Typhi *Salmonella* infections increased from 0.11/100,000 in 1996 to 0.25/100,000 in 2002.

**Discussion:** These data emphasize the need for additional efforts to reduce the emergence of fluoroquinolone-resistant non-Typhi *Salmonella*.